Telomir Pharmaceuticals, Inc. (TELO) Q1 2026 Earnings
TELO·Reported May 14, 2026·After market close
Diluted EPS came in at $-0.03 (+57.1% YoY), beat the $-0.07 consensus by $0.04.
Diluted EPS
$-0.03beat by $0.04
Consensus: $-0.07
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Telomir Pharmaceuticals, Inc.'s Q1 2026 earnings report.
Telomir Pharmaceuticals, Inc. (TELO) reported Q1 2026 earnings on May 14, 2026 after market close.
Telomir Pharmaceuticals, Inc. reported diluted EPS of $-0.03 for Q1 2026.
EPS beat the consensus estimate of $-0.07 by $0.04.
Compared to the same quarter a year prior, diluted EPS grew 57.1% from $-0.07.
You can read the 10-Q periodic report (0001493152-26-023010) directly on SEC EDGAR. The filing index links above go to sec.gov.